Gamma Knife® stereotactic radiosurgery as a treatment for essential and parkinsonian tremor: long-term experience

被引:7
|
作者
Perez-Sanchez, J. R. [1 ]
Martinez-Alvarez, R. [2 ]
Moreno, N. E. Martinez [2 ]
Diaz, C. Torres [2 ,3 ]
Rey, G. [2 ]
Parees, I. [1 ]
Del Barrio, A. A. [1 ]
Alvarez-Linera, J. [4 ]
Kurtis, M. M. [1 ]
机构
[1] Hosp Ruber Int, Serv Neurol, Unidad Trastornos Movimiento, Madrid, Spain
[2] Hosp Ruber Int, Serv Radiocirugia & Neurocirugia Func, Madrid, Spain
[3] Hosp Univ Princesa, Serv Neurocirugia, Madrid, Spain
[4] Hosp Ruber Int, Serv Radiol, Madrid, Spain
来源
NEUROLOGIA | 2023年 / 38卷 / 03期
关键词
Radiosurgery; Gamma Knife; Essential tremor; Parkinson's disease; Thalamotomy; DEEP BRAIN-STIMULATION; FOCUSED ULTRASOUND; CLINICAL-DIAGNOSIS; THALAMOTOMY; DISEASE; MANAGEMENT;
D O I
10.1016/j.nrl.2020.05.014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Unilateral Gamma Knife (TM) stereotactic radiosurgery on the ventral-intermediate nucleus of the thalamus is a minimally invasive neurosurgical option for refractory tremor. We describe the experience of Gamma Knife (TM) thalamotomy (GKT) in patients with essential tremor (ET) and tremor-dominant Parkinson's disease (PD) at our specialised stereotactic neurosurgery unit. Methods: We reviewed the cases of patients treated with GKT between January 2014 and February 2018 with a minimum of 12 months' follow-up. We analysed clinical and demographic variables, indication, radiation dose, effectiveness (based on subscales of the Fahn-Tolosa-Marin [FTM] scale and the Movement Disorders Society-Unified Parkinson's Disease Rating Scale [MDS-UPDRS] motor score), and adverse events. Results: Thirteen patients were registered, 6 with a diagnosis of tremor-dominant PD, four with refractory ET, and three with ET and PD. Median age was 78 years (range, 62-83), with seven patients aged over 75 years. Four patients were receiving anticoagulants and two had history of stroke. The maximum radiation dose administered was 130 Gy. Mean (standard deviation) follow-up duration was 30.0 (14.5) months. Significant tremor improvement was observed on the FTM subscales: 63.6% at 12 months and 63.5% at the end of follow-up; MDS-UPDRS tremor items showed improvements of 71.3% at 12 months and 60.3% at the end of follow up. Eleven patients reported significant improvements in quality of life, and 3 reported mild and transient adverse effects. Conclusions: This is the largest series of patients with essential and parkinsonian tremor trea-ted with GKT and followed up in the long term in Spain. GKT can be safe and effective in the long term in patients with refractory tremor, including in elderly patients and those receiving anticoagulants. (c) 2020 Sociedad Espan similar to ola de Neurologi ' a. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Long-Term Outcomes Following Gamma Knife Radiosurgery in the Treatment of Nonsecretory Pituitary Adenomas
    Gopalan, Rupa
    Basina, Bhuvaneswara
    Khaled, Mohamed A.
    Sheehan, Jason P.
    JOURNAL OF NEUROSURGERY, 2010, 113 (02) : A441 - A442
  • [42] Long-term results of Gamma Knife® Radiosurgery for the Treatment of petroclival and Cavernous Sinus Meningiomas
    Wolff, R.
    Heyd, R.
    Roedel, C.
    Seifert, V
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 : 85 - 85
  • [43] Gamma knife radiosurgery for essential tremor: A Case report and review of the literature
    Elaimy, Ameer L.
    Demakas, John J.
    Arthurs, Benjamin J.
    Cooke, Barton S.
    Fairbanks, Robert K.
    Lamoreaux, Wayne T.
    Mackay, Alexander R.
    Greeley, David R.
    Lee, Christopher M.
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2010, 8
  • [44] Effects on Gait and Balance of VIM Gamma Knife Radiosurgery in Essential Tremor
    Mira, Valentin
    Zwaard, Babette
    Boutin, Emmanuelle
    Guillaud, Etienne
    Cretol, Axelle
    Regis, Jean
    Azulay, Jean-Philippe
    Witjas, Tatiana
    Vaugoyeau, Marianne
    STEREOTACTIC AND FUNCTIONAL NEUROSURGERY, 2024, 102 (05) : 284 - 292
  • [45] GAMMA KNIFE RADIOSURGERY (GKRS) IN THE MANAGEMENT OF PARKINSON'S DISEASE AND ESSENTIAL TREMOR : LONG-TERM FOLLOW-UP REPORT OF 196 CASES
    Mojica, R.
    Mark, R.
    Smith, H.
    Akins, R.
    Nair, M.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S361 - S361
  • [46] Gamma Knife Radiosurgery (GKRS) in the Management of Parkinson's Disease and Essential Tremor: Long-term Follow-up Report of 196 Cases
    Mark, R. J.
    White, D.
    Akins, R.
    Mutyala, S.
    Jacques, D.
    Young, R.
    Chen, C.
    Nair, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S39 - S39
  • [47] Gamma Knife Radiosurgery (GKRS) in the Management of Parkinson's Disease and Essential Tremor: Long-Term Follow-Up Report of 195 Cases
    Mark, Rufus
    Smith, Harold
    Jacques, Skip
    Young, Ron
    Akins, Scott
    Chen, Ching
    Nair, Murali
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 196 - 196
  • [48] Gamma Knife Radiosurgery (GKRS) in the Management of Parkinson's Disease and Essential Tremor: Long-term Follow-up Report of 192 Cases
    Frentress, C.
    Mark, R. J.
    Smith, H.
    Jacques, D.
    Young, R.
    Copcutt, B.
    Chen, C.
    Anderson, P. J.
    Nair, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S7 - S7
  • [49] GAMMA KNIFE RADIOSURGERY (GKRS) IN THE MANAGEMENT OF PARKINSON'S DISEASE AND ESSENTIAL TREMOR: LONG-TERM FOLLOW-UP REPORT OF 190 CASES
    Frentress, C.
    Mark, R.
    Smith, H.
    Jacques, D.
    Young, R.
    Copcutt, B.
    Chen, C.
    Anderson, P.
    Nair, M.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S260 - S261
  • [50] Gamma Knife Radiosurgery (GKRS) in the Management of Parkinson's Disease and Essential Tremor: Long-Term Follow-Up Report of 186 Cases
    Mark, Rufus
    Smith, Harold
    Jacques, Deane
    Young, Ronald
    Copcutt, Brian
    Chen, Ching
    Anderson, Paul
    Akins, Robin
    Nair, Murali
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 199 - 199